Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
| Autor: | Uri Elkayam, C S Liang, Michael M. Givertz, A.D. Johnson, W H Haught, William T. Abraham, Lynne E. Wagoner, M Neibaur, Thierry H. LeJemtel, Wilson S. Colucci, D P Horton, Robert C. Bourge |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Nesiritide
medicine.medical_specialty medicine.drug_class business.industry Cardiac index General Medicine Placebo medicine.disease law.invention Atrial natriuretic peptide Randomized controlled trial law Internal medicine Heart failure Natriuretic peptide medicine Cardiology Decompensation business Intensive care medicine medicine.drug |
| Zdroj: | New England Journal of Medicine. 343:246-253 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejm200007273430403 |
| Popis: | Background Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has beneficial hemodynamic effects in patients with decompensated congestive heart failure. We investigated the clinical use of nesiritide in such patients. Methods Patients hospitalized because of symptomatic congestive heart failure were enrolled in either an efficacy trial or a comparative trial. In the efficacy trial, which required the placement of a Swan–Ganz catheter, 127 patients with a pulmonary-capillary wedge pressure of 18 mm Hg or higher and a cardiac index of 2.7 liters per minute per square meter of body-surface area or less were randomly assigned to double-blind treatment with placebo or nesiritide (infused at a rate of 0.015 or 0.030 μg per kilogram of body weight per minute) for six hours. In the comparative trial, which did not require hemodynamic monitoring, 305 patients were randomly assigned to open-label therapy with standard agents or nesiritide for up to seven days. Results In the efficacy trial, ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|